Important Notice: Our web hosting provider recently started charging us for additional visits, which was unexpected. In response, we're seeking donations. Depending on the situation, we may explore different monetization options for our Community and Expert Contributors. It's crucial to provide more returns for their expertise and offer more Expert Validated Answers or AI Validated Answers. Learn more about our hosting issue here.

What does the Boehringer Ingelheims Venture Capitel Fund aim for?

April 26, 2017aim Boehringer fund Ingelheim venture

0

Posted

What does the Boehringer Ingelheims Venture Capitel Fund aim for?

1 Answer

0

Posted

Boehringer Ingelheim has launched its corporate venture capital fund, the Boehringer Ingelheim Venture Fund (BIVF) on 30 March 2010. The BIVF aims to invest in Biotech and Start-up companies that provide ground-breaking therapeutic approaches and technologies to help drive innovation in medical science. These may include – but are not limited to – new therapeutic concepts including stem cells and RNA silencing as well as new generation vaccines, new generation protein or antibody technologies, new molecular targets and/or first-in-class lead compounds. Disease-related biomarkers would be an additional area of focus. Investment opportunities will be sought on a worldwide basis. For further information about the BIVF, please visit our related website.